Ralph D'Agostino to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Ralph D'Agostino has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.317
-
Lanier CM, Razavian NB, Smith S, D'Agostino RB, Hughes RT. The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303. Leuk Lymphoma. 2024 Dec; 65(14):2199-2206.
Score: 0.171
-
Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.
Score: 0.103
-
Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614.
Score: 0.025
-
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R, Torti SV, Torti FM. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6728-37.
Score: 0.017